Pharma BD Deal Intelligence
Under the terms of the agreement, Lexicon will receive an upfront payment of $300 million and is eligible to receive development, regulatory and sales…
Lexicon fires back after Sanofi ends up-to-$1.7B diabetes collaboration. Total deal potential was $1.7 billion including $300 million upfront and $1.4 billion…
Sanofi partners with Lexicon Pharmaceuticals to develop sotagliflozin, with Lexicon receiving a $300 million upfront payment and eligibility for up to…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Sanofi licensed sotagliflozin, a dual SGLT1/SGLT2 inhibitor, from Lexicon for global development and commercialization in diabetes and cardiovascular disease. Lexicon received $300M upfront, $100M equity, with up to $2.42B in milestones. The deal was terminated by Sanofi in 2019 following regulatory setbacks. Lexicon later independently obtained approval for Inpefa (sotagliflozin) for heart failure in 2023.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Sanofi SA / Lexicon Pharmaceuticals Inc. (this deal) | 2015 | $1.7B | 44 |
| Sanofi SA / Regeneron Pharmaceuticals, Inc. | 2007 | $1.0B | 97 |
| Sanofi SA / Synthelabo S.A. | 1998 | $11.0B | 84 |
| Sanofi SA / Genzyme Corporation | 2011 | $20.1B | 84 |
| Sanofi SA / Amunix Pharmaceuticals Inc. | 2021 | $1.2B | 76 |
| Sanofi SA / Genzyme Corporation | 2010 | $18.5B | 75 |
| Sanofi SA / Translate Bio Inc. | 2018 | $805M | 73 |
← Browse all deals · How we score deals
More: 2015 deals · Sanofi SA deals · Cardiovascular deals